Isofol Medical AB (publ) (STO:ISOFOL)
Sweden · Delayed Price · Currency is SEK | Market Cap | 222.42M +14.9% |
| Revenue (ttm) | n/a |
| Net Income | -55.57M |
| EPS | -0.22 |
| Shares Out | 320.49M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 70,086 |
| Open | 0.6990 |
| Previous Close | 0.6980 |
| Day's Range | 0.6900 - 0.7050 |
| 52-Week Range | 0.5515 - 1.2790 |
| Beta | 1.00 |
| Analysts | n/a |
| Price Target | 3.60 (+418.73%) |
| Earnings Date | May 19, 2026 |
About Isofol Medical AB
Isofol Medical AB (publ) operates as a clinical stage biotech company. It develops arfolitixorin, which is in phase Ib/II clinical trial for the treatment of metastatic colorectal cancer. The company was incorporated in 2008 and is based in Gothenburg, Sweden. [Read more]
Financial Performance
Financial StatementsNews
Isofol Medical AB Quarterly report: Q1 2026
Isofol Medical AB has published its Q1 2026 quarterly earnings report on May 19, 2026.
Isofol Medical AB Slides: FY 2026
Isofol Medical AB has posted slides in relation to its FY 2026 quarterly earnings report, which was published on March 10, 2026.
Isofol Medical AB Slides: Corporate presentation
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on March 9, 2026.
Isofol Medical AB Annual report: Q4 2025
Isofol Medical AB has published its Q4 2025 annual report on February 18, 2026.
Isofol Medical AB Quarterly report: Q4 2025
Isofol Medical AB has published its Q4 2025 quarterly earnings report on February 18, 2026.
Isofol Medical AB Slides: Corporate presentation
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on February 3, 2026.
Isofol Medical AB Slides: ABGSC Investor Days
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on December 4, 2025.
Isofol Medical AB Transcript: Investor Update
Multiple clinical and financial milestones have been achieved, including a successful rights issue, FDA and Japanese regulatory progress, and a new patent extending exclusivity to 2043. The ongoing phase 1B/2 study is advancing with higher, well-tolerated doses and an improved design, supporting strong commercial and scientific potential.
Isofol Medical AB Slides: Investor Update
Isofol Medical AB has posted slides in relation to its latest quarterly earnings report, which was published on November 13, 2025.
Isofol Medical AB Quarterly report: Q3 2025
Isofol Medical AB has published its Q3 2025 quarterly earnings report on November 12, 2025.
Isofol Medical AB Earnings Call Transcript: Q2 2025
Exited the quarter with a strengthened financial position after an oversubscribed rights issue and continued progress in clinical trials. R&D expenses increased, resulting in a higher net loss, but positive regulatory feedback and new partnerships support future growth.
Isofol Medical AB Quarterly report: Q2 2025
Isofol Medical AB has published its Q2 2025 quarterly earnings report on August 26, 2025.